Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

Annals of Neurology

Volumn 46, Issue 6, 1999, Pages 860-866

  McLean, Catriona A ^a,b   Cherny, Robert A ^a,b   Fraser, Fiona W ^a,b   Fuller, Stephanie J ^a,b   Smith, Margaret J ^a   Beyreuther, Konrad ^c   Bush, Ashley I ^a,b,d   Masters, Colin L ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; GENE LOCATION; GENE POOL; HUMAN; HUMAN TISSUE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; AGED; ANTIBODY SPECIFICITY; BRAIN; BRAIN CORTEX; CEREBELLUM; COMPARATIVE STUDY; DOWN SYNDROME; GENETICS; HIPPOCAMPUS; HOSPITALIZATION; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUROLOGIC DISEASE; PATHOLOGY; PUTAMEN; REFERENCE VALUE; REGRESSION ANALYSIS; SOLUBILITY; THALAMUS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CEREBELLUM; CEREBRAL CORTEX; DOWN SYNDROME; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; NERVOUS SYSTEM DISEASES; ORGAN SPECIFICITY; PUTAMEN; REFERENCE VALUES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SOLUBILITY; THALAMUS;

EID: 0032590054     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M     Document Type: Article

References (41)

1. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120: 885-890
2. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985;82:4245-4249
3. Hyman BT, Tanzi RE. Amyloid, dementia and Alzheimer's disease. Curr Opin Neurol Neurosurg 1992;5:88-93
4. Berg L, McKeel DW, Miller P, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-335
5. McKee AC, Kosik KS, Kowall NW. Neuritic pathology and dementia in Alzheimer's disease. Ann Neurol 1991;30:156-165
6. Dickson DW, Crystal HA, Bevona C, et al. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995;16:285-297
7. Cummings BJ, Pike CJ, Dhankle R, Cotman CW. β-Amyloid deposition and other measures of neuropathology predict cognitive status in Alheimer's disease. Neurobiol Aging 1996;17: 921-933
8. 1-42/43) of amyloid β protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 1994;205:834-842
9. Funato K, Yoshimura M, Kusui K, et al. Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease. Am J Pathol 1998;152:1633-1640
10. Delacourte A, Buée L, David J-P, et al. Lack ot continuum between cerebral aging and Alzheimer's disease as revealed by PHF-tau and Aβ biochemistry. Alzheimers Rep 1998;1:101-110
11. Shinkai Y, Yoshimura M, Morishima-Kawashima M, et al. Amyloid β-protein deposition in the leptomeninges and cerebral cortex. Ann Neurol 1997;42:899-908
12. Nakabayashi J, Yoshimura M, Morishima-Kawashima M, et al. Amyloid β-protein (Aβ) accumulation in the putamen and mammillary body during aging and in Alzheimer disease. J Neuropathol Exp Neurol 1998;57:343-352
13. Shoji M, Harigaya Y. Biochemical heterogeneity of Alzheimer's disease. Neuropathology 1998;18:116-120
14. Kuo Y-M, Emmerling MR, Vigo-Pelfrey C, et al. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996;271:4077-4081
15. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part III. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486
16. Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J Biol Chem 1999;274:23223-23228
17. Ida N, Hartmann T, Pantek J, et al. Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive western blot assay. J Biol Chem 1996;271:22908-22914
18. Price DL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991; 12:295-312
19. Blacker D, Tanzi RE. The genetics of Alzheimer disease: current status and future prospects. Neurol Rev 1998;55:294-296
20. Duyckaerts C, Hauw, J. Diagnosis and staging of Alzheimer disease. Neurobiol Aging 1997;18(Suppl):S33-S42
21. Arriagada PV, Growdon JH, Hedley-White E, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639
22. Harigaya Y, Shoji M, Kawarabayashi T, et al. Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. Biochem Biophys Res Commun 1995;211:1015-1022
23. Teller JK, Russo C, DeBusk LM, et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996;2:93-95
24. Tabaton M, Nunzi M, Xue R, et al. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 1994;200:1598-1603
25. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102
26. Oyama F, Sawamura N, Kobayashi K, et al. Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid β-protein 42 in the brain. J Neurochem 1998;71:313-322
27. Enya M, Morishima-Kawashima M, Yoshimura M, et al. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol 1999; 154:271-279
28. Haass C, Hung AY, Schlossmacher MG, et al. β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem 1993;268:3021-3024
29. Higgins LS, Murphy GM, Forno LS, et al. p3 β-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Am J Pathol 1996;149:585-596
30. Gouras GK, Xu HX, Jovanovic JN, et al. Generation and regulation of β-amyloid peptide variants by neurons. J Neurochem 1998;71:1920-1925
31. Gowing E, Roher AE, Woods AS, et al. Chemical characterization of the Aβ17-42 peptide, a component of diffuse amyloid deposits of Alzheimer's disease. J Biol Chem 1994;269:10987-10990
32. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321-339
33. Morishima-Kawashima M, Ihara Y. The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 1998;37:15247-15253
34. Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 1993;52:594-600
35. Tienari PJ, Ida N, Ikonen E, et al. Intracellular and secreted Alzheimer β-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. Proc Natl Acad Sci USA 1997;94:4125-4130
36. Skovronsky DM, Doms RW, Lee VMY. Detection of a novel intraneural pool of insoluble amyloid β protein that accumulates with time in culture. J Cell Biol 1998;141:1031-1039
37. Savage MJ, Trusko SP, Howland DS, et al. Turnover of amyloid β-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 1998;18:1743-1752
38. Roses AD. Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis 1997;4:170-186
39. Blacker D, Wilcox MA, Laird NM, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998;19:357-360
40. Wang J, Dickson DW, Trojanowski JQ, Lee VM-Y. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999;158: 328-337
41. Lue L-F, Kuo Y-M, Roher AE, et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155:853-862